adminSebastian Sandler
JPMorgan Chase & Co, Research Division
Great. Thanks, everyone, for joining us. I’m pleased to be joined by the Adaptive team. My name is Sebastian Sandler from Life Science Tools and Diagnostics team at JPMorgan. As usual, we’ll have 20 or so minutes of presentation, followed by Q&A. And with that, I’ll pass it off to Chad. Thanks, Chad.
Chad Robins
Co-Founder, CEO & Chairman
Thank you, Sebastian, for the opportunity to present at JPMorgan once again. Happy New Year to all of you in the room, and welcome to those of you who are listening on the webcast. As a quick reminder, I will be making forward-looking statements during my presentation, and I and my team will be as well during the Q&A.
For those of you who are new to Adaptive, let me give you a quick refresher of who we are. My brother, Harlan and I founded the company 16 years ago at the Fred Hutchinson Cancer Research Institute, and we’ve been public since 2019. Today, we’re about 620 employees. We’ve got more than $275 million in revenue and a strong cash position of approximately $227 million.
Adaptive was built on a simple but powerful premise that if we could read and translate the genetic source code of the adaptive immune system, T cells and B cells, we could fundamentally improve how diseases are diagnosed and understood.
So as our proprietary platform and underlying
Read the full article here
